A prospective randomised controlled trial to determine the early and late reactions after the use of iopamidol 340 (Niopam™) and iomeprol 350 (Iomeron®) in cardiac catheterisation

The incidence of early adverse reactions was similar with the two non-ionic contrast agents. Although bradycardia was slightly more frequent using iopamidol 340, nausea was reported more commonly 24 h after the procedure in patients receiving Iomeron 350 (Iomeron®). We conclude that there were only minor clinical differences between these agents; both are safe and well tolerated.